RT Journal Article SR Electronic T1 Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3541 OP 3547 VO 36 IS 7 A1 OYEON CHO A1 MISON CHUN A1 SUK-JOON CHANG A1 YOUNG-TAEK OH A1 O KYU NOH YR 2016 UL http://ar.iiarjournals.org/content/36/7/3541.abstract AB Aim: To investigate whether common terminology criteria for adverse events (CTCAE) grade 4 lymphopenia (<200 cells/μl) during concurrent chemoradiotherapy (CCRT) is relevant to poor survival. Patients and Methods: We analyzed 124 patients with newly diagnosed Federation of Gynecology and Obstetrics (FIGO) stage I-III cervical cancer who received weekly cisplatin-based CCRT and brachytherapy using Kaplan-Meier curves and the Cox proportional hazard models. Results: Grade 4 lymphopenia significantly predicted disease-specific survival (DSS) and progression-free survival (PFS) (adjusted hazard ratio (95% confidence interval (CI))=3.6 (1.37-9.44), p=0.009 and 3.28 (1.27-8.48), p=0.014, respectively). The 5-year DSS and 3-year PFS were significantly higher among patients with grade 2-3 lymphopenia (≥200 cells/μl) than among those with grade 4 lymphopenia (84.8% vs. 50.4%, p<0.001, and 80.7% vs. 50%, p=0.002, respectively). Conclusion: Severe lymphopenia during CCRT could predict poor survival.